To evaluate safety and efficacy of weekly ( qw ) and every other week ( q2w ) dosing of sarilumab , a fully human anti-interleukin 6 receptor ( anti-IL-6R ) monoclonal antibody , for moderate-to-severe rheumatoid arthritis ( RA ) .